Invest in the future, invest in EVOQ
EVOQ crafts metamaterial solutions with atomic precision, unlocking transformative applications in healthcare, energy, textiles, and beyond. Join a platform poised for global impact.
Pioneering metamaterial technology
The EVOQ metamaterial technology platform patented high-energy laser ablation process transforms any solid metal from the periodic table into metamaterials—perfectly spherical, monodisperse particles. These non-ionic, stable materials integrate seamlessly into products, enhancing their performance and precision. From medical devices to energy storage, our scalable platform addresses critical challenges with unmatched reliability, reducing production costs by up to 500x compared to traditional methods.
Precision meets versatility
No ion emission
Stable metamaterial without an oxidative layer that functions without shedding ions.
Clinically safe
No cytotoxicity or disruption to the human body with high biocompatibility.
Platform-ready
Integrates into polymers, coatings, textiles, and finished goods and remains performant.
Scalable
Cost-effective production reduces costs up to 500x vs. traditional methods.
Scalable revenue
Perpetual licensing fees
Partners gain continuous access to metamaterials from the EVOQ platform technology through ongoing licensing fees, ensuring sustained collaboration, reliable material supply, and innovation across diverse product applications without interruption.
Exclusivity payments
Select partnerships include upfront payments for market exclusivity, granting partners sole access to metamaterials from the EVOQ platform technology in specific sectors, enhancing competitive advantage and fostering tailored, high-impact solutions.
Broad reach
The EVOQ platform technology spans healthcare, textiles, electronics, and beyond, enabling wide-ranging applications. This versatility drives deep market expansion, empowering innovators to address unique challenges across diverse industries.
Medical devices
Our metamaterial achieves a high antimicrobial affect across all tested pathogens, eliminating encrustation with no cytotoxicity or blood impact, validated across four integration methods.
Inhaled therapeutics
Funded by the Cystic Fibrosis Foundation, our metamaterial demonstrate 100% efficacy against 64 drug-resistant strains, with no resistance or adverse effects in high-dose studies.
Textiles and surfaces
FUZE treats textiles and surfaces in 17 countries, offering antimicrobial efficacy after hundreds of washes. ExpeDRY gold treatment for down feathers cuts dry time by 50% and eliminates clumping.
Battery enhancement
Gold particles stabilize battery structures, eliminate corrosion, and boost capacity by up to 700%, redefining energy storage.
Why Invest in EVOQ?
EVOQ offers compelling value for investors:
- Scalable platform: Broad applications in high-growth markets.
- Proven results: Validated in clinical trials and partnerships with 150+ global brands.
- IP-protected: Patented process ensures exclusivity.
- High returns: Licensing model drives consistent, profitable revenue.
Join the future
EVOQ seeks strategic partners and capital to expand manufacturing, advance clinical programs, and secure regulatory approvals. Find equity in a high-growth, IP-protected platform. Build partnerships in medtech, bio, textiles, energy, and many more. Co-development emerging verticals with massive potential. The opportunity is vast. Are you ready to shape the future?
Submit inquiry